Adonis

Who owns Adonis?

Adonis is an American Healthcare company, currently owned by Quadrille Capital since 2026.

About Adonis

Adonis is a New York-based healthcare technology company whose software platform automates revenue cycle management for hospitals, health systems and medical groups, coordinating billing, claims and payments across electronic health records, patient portals and clearinghouses. Its platform is organized around three modules: Intelligence, which analyzes revenue cycle performance and surfaces leakage; AI Agents, which autonomously detect issues and progress claims; and Orchestration, which sequences those automations across a provider's systems. It competes in the AI-driven revenue cycle management segment, positioning its technology against the denials, underpayments and workforce shortages that weigh on provider finances. The company counts healthcare organizations including Mount Sinai Health System among its clients and reports more than fourfold revenue growth in 2025 with net revenue retention above 130 percent.

Ownership journey

Adonis was founded in New York in 2022 by brothers Akash and Aman Magoon to rebuild healthcare revenue cycle operations around automation and machine intelligence. Backed from its early stages by growth and venture investors, the company had raised more than USD 95 million in total funding by early 2026. In March 2026 it closed a USD 40 million Series C round led by Quadrille Capital, investing through its Quadrille Technologies V strategy, as a minority growth investor rather than a controlling shareholder. Quadrille remains an active backer of the business and no exit or secondary transaction has been recorded.

Under PE ownership

The Series C capital was earmarked for product development, commercial expansion and hiring rather than a change of control. Adonis said it would deepen investment across its Intelligence, AI Agents and Orchestration modules, extend its presence in the health system market, and continue expanding its New York-based team. The round followed a year of more than fourfold revenue growth in 2025 and net revenue retention above 130 percent, according to company disclosures. Because the investment closed only in early 2026, its operational effects are still emerging.